PCA
SRPT icon

Pallas Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Pallas Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,152
Closed -$264K – 1093
2026
Q1 		$264K Sell
12,152
-11,744
-49% -$227K 0.01% 677
2025
Q4 		$514K Buy
+23,896
New +$504K 0.02% 521

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Pallas Capital Advisors's SRPT Position: Q2 2026 in Review

Pallas Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 12,152 shares — an estimated $264K sold.

Pallas Capital Advisors first reported a position in SRPT in Q4 2025 and held it in 2 quarters. The position peaked at $514K in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Pallas Capital Advisors reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pallas Capital Advisors sold 12,152 Sarepta Therapeutics shares in Q2 2026, an estimated $264K.
  • Pallas Capital Advisors first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 2 quarters.
  • Pallas Capital Advisors's Sarepta Therapeutics position peaked at $514K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.